Artificial intelligence (AI) in rare diseases: Is the future brighter?

Sandra Brasil, Carlota Pascoal, Rita Francisco, Vanessa dos Reis Ferreira, Paula A. Videira, Gonçalo Valadão

Research output: Contribution to journalReview article

Abstract

The amount of data collected and managed in (bio)medicine is ever-increasing. Thus, there is a need to rapidly and efficiently collect, analyze, and characterize all this information. Artificial intelligence (AI), with an emphasis on deep learning, holds great promise in this area and is already being successfully applied to basic research, diagnosis, drug discovery, and clinical trials. Rare diseases (RDs), which are severely underrepresented in basic and clinical research, can particularly benefit from AI technologies. Of the more than 7000 RDs described worldwide, only 5% have a treatment. The ability of AI technologies to integrate and analyze data from different sources (e.g., multi-omics, patient registries, and so on) can be used to overcome RDs’ challenges (e.g., low diagnostic rates, reduced number of patients, geographical dispersion, and so on). Ultimately, RDs’ AI-mediated knowledge could significantly boost therapy development. Presently, there are AI approaches being used in RDs and this review aims to collect and summarize these advances. A section dedicated to congenital disorders of glycosylation (CDG), a particular group of orphan RDs that can serve as a potential study model for other common diseases and RDs, has also been included.

Original languageEnglish
Article number978
JournalGenes
Volume10
Issue number12
DOIs
Publication statusPublished - 1 Dec 2019

Fingerprint

Artificial Intelligence
Rare Diseases
Congenital Disorders of Glycosylation
Technology
Aptitude
Information Storage and Retrieval
Drug Discovery
Research
Registries
Medicine
Clinical Trials
Learning
Therapeutics

Keywords

  • Artificial intelligence
  • Big data
  • Congenital disorders of glycosylation
  • Diagnosis
  • Drug repurposing
  • Machine learning
  • Personalized medicine
  • Rare diseases

Cite this

@article{21679e80a78d4955a21a95c45d438c36,
title = "Artificial intelligence (AI) in rare diseases: Is the future brighter?",
abstract = "The amount of data collected and managed in (bio)medicine is ever-increasing. Thus, there is a need to rapidly and efficiently collect, analyze, and characterize all this information. Artificial intelligence (AI), with an emphasis on deep learning, holds great promise in this area and is already being successfully applied to basic research, diagnosis, drug discovery, and clinical trials. Rare diseases (RDs), which are severely underrepresented in basic and clinical research, can particularly benefit from AI technologies. Of the more than 7000 RDs described worldwide, only 5{\%} have a treatment. The ability of AI technologies to integrate and analyze data from different sources (e.g., multi-omics, patient registries, and so on) can be used to overcome RDs’ challenges (e.g., low diagnostic rates, reduced number of patients, geographical dispersion, and so on). Ultimately, RDs’ AI-mediated knowledge could significantly boost therapy development. Presently, there are AI approaches being used in RDs and this review aims to collect and summarize these advances. A section dedicated to congenital disorders of glycosylation (CDG), a particular group of orphan RDs that can serve as a potential study model for other common diseases and RDs, has also been included.",
keywords = "Artificial intelligence, Big data, Congenital disorders of glycosylation, Diagnosis, Drug repurposing, Machine learning, Personalized medicine, Rare diseases",
author = "Sandra Brasil and Carlota Pascoal and Rita Francisco and Ferreira, {Vanessa dos Reis} and Videira, {Paula A.} and Gon{\cc}alo Valad{\~a}o",
note = "SFRH/BD/138647/2018. SFRH/BD/124326/2016.",
year = "2019",
month = "12",
day = "1",
doi = "10.3390/genes10120978",
language = "English",
volume = "10",
journal = "Virus Genes",
issn = "0920-8569",
publisher = "Springer Science Business Media",
number = "12",

}

Artificial intelligence (AI) in rare diseases: Is the future brighter? / Brasil, Sandra; Pascoal, Carlota; Francisco, Rita; Ferreira, Vanessa dos Reis; Videira, Paula A.; Valadão, Gonçalo.

In: Genes, Vol. 10, No. 12, 978, 01.12.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Artificial intelligence (AI) in rare diseases: Is the future brighter?

AU - Brasil, Sandra

AU - Pascoal, Carlota

AU - Francisco, Rita

AU - Ferreira, Vanessa dos Reis

AU - Videira, Paula A.

AU - Valadão, Gonçalo

N1 - SFRH/BD/138647/2018. SFRH/BD/124326/2016.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The amount of data collected and managed in (bio)medicine is ever-increasing. Thus, there is a need to rapidly and efficiently collect, analyze, and characterize all this information. Artificial intelligence (AI), with an emphasis on deep learning, holds great promise in this area and is already being successfully applied to basic research, diagnosis, drug discovery, and clinical trials. Rare diseases (RDs), which are severely underrepresented in basic and clinical research, can particularly benefit from AI technologies. Of the more than 7000 RDs described worldwide, only 5% have a treatment. The ability of AI technologies to integrate and analyze data from different sources (e.g., multi-omics, patient registries, and so on) can be used to overcome RDs’ challenges (e.g., low diagnostic rates, reduced number of patients, geographical dispersion, and so on). Ultimately, RDs’ AI-mediated knowledge could significantly boost therapy development. Presently, there are AI approaches being used in RDs and this review aims to collect and summarize these advances. A section dedicated to congenital disorders of glycosylation (CDG), a particular group of orphan RDs that can serve as a potential study model for other common diseases and RDs, has also been included.

AB - The amount of data collected and managed in (bio)medicine is ever-increasing. Thus, there is a need to rapidly and efficiently collect, analyze, and characterize all this information. Artificial intelligence (AI), with an emphasis on deep learning, holds great promise in this area and is already being successfully applied to basic research, diagnosis, drug discovery, and clinical trials. Rare diseases (RDs), which are severely underrepresented in basic and clinical research, can particularly benefit from AI technologies. Of the more than 7000 RDs described worldwide, only 5% have a treatment. The ability of AI technologies to integrate and analyze data from different sources (e.g., multi-omics, patient registries, and so on) can be used to overcome RDs’ challenges (e.g., low diagnostic rates, reduced number of patients, geographical dispersion, and so on). Ultimately, RDs’ AI-mediated knowledge could significantly boost therapy development. Presently, there are AI approaches being used in RDs and this review aims to collect and summarize these advances. A section dedicated to congenital disorders of glycosylation (CDG), a particular group of orphan RDs that can serve as a potential study model for other common diseases and RDs, has also been included.

KW - Artificial intelligence

KW - Big data

KW - Congenital disorders of glycosylation

KW - Diagnosis

KW - Drug repurposing

KW - Machine learning

KW - Personalized medicine

KW - Rare diseases

UR - http://www.scopus.com/inward/record.url?scp=85075672800&partnerID=8YFLogxK

U2 - 10.3390/genes10120978

DO - 10.3390/genes10120978

M3 - Review article

VL - 10

JO - Virus Genes

JF - Virus Genes

SN - 0920-8569

IS - 12

M1 - 978

ER -